O-6 EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—an open-label randomized controlled phase II study
Titel:
O-6 EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—an open-label randomized controlled phase II study
Auteur:
Smyth, E. Mauer, M. Cella, C. Ben-Aharon, I. Piessen, G. Wyrwicz, L. Al-Haidari, G. Kanonnikoff, T. Fleitas Boige, V. Stahl, M. Martens, U. Obermannová, R. Gomez-Martin, C. Thuss-Patience, P. Arrazubi, V. Avallone, A. Shiu, K. Collienne, M. Giraut, A. Lordick, F.